Naim Alkhouri, Louise Campbell and Roger Green are joined by new guest, Prof. James O’Beirne, to discuss developing improved models for patient identification and risk stratification. Learning from past experiences with HCV, the LOCATE-NAFLD study was born and this episode dives into the project protocols, aims and potential takeaways.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation hones in on what the audience can expect and look forward to learn more about in the coming months.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation discusses the growing trend of patient involvement, the factors for and benefits of NIT development, lessons from artificial intelligence and more.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation focuses largely on the various challenges associate with adopting and communicating new nomenclature for liver disease.
On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation From the Vault to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation focuses on the increasing importance of omics and potentially powerful weight-loss therapies presented at the ADA meeting. Other major themes in this session include insights on the role of artificial intelligence and epigenetics.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation digs deeper into the FASCINATE-2 interim analysis data at week 26 of the 52-week trial. The discussion develops into practical and plausible considerations in a comparison between injectable and oral agents.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This final session focuses on another paper by Vincent Wong which sparks discussion around the plausibility of shifting from biopsy to NITs and the cost effectiveness and frequency of testing.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This session focuses on a study aimed at connecting steatotic liver disease in patients without cirrhosis to HCC outcomes over a ten year period. After, the group unpacks how little is known about the mechanisms of fibrosis resolution.
